hologic , inc .notes to consolidated financial statements ( continued ) ( in thousands , except per share data ) purchased products that the company continues to sell as well as utilize to enhance and incorporate into the company 2019s existing products .the intangible assets are expected to be amortized on a straight-line basis over the expected useful lives as the anticipated undiscounted cash flows are relatively consistent over the expected useful lives of the intangible assets .the estimated $ 600 of purchase price allocated to in-process research and development projects related to aeg 2019s organic photoconductor coating and selenium product lines .the deferred income tax liability relates to the tax effect of acquired identifiable intangible assets , and fair value adjustments to acquired inventory , land , building and related improvements as such amounts are not deductible for tax purposes .the company had an existing relationship with aeg as a supplier of inventory items .the supply agreement was entered into in prior years at arm 2019s length terms and conditions .no minimum purchase requirements existed and the pricing was consistent with other vendor agreements .acquisition of r2 technology , inc .on july 13 , 2006 , the company completed the acquisition of r2 technology , inc .( r2 ) pursuant to an agreement and plan of merger dated april 24 , 2006 .the results of operations for r2 have been included in the company 2019s consolidated financial statements from the date of acquisition as part of its mammography/breast care business segment .r2 , previously located in santa clara , california , develops and sells computer-aided detection technology and products ( cad ) , an innovative technology that assists radiologists in the early detection of breast cancer .the aggregate purchase price for r2 of approximately $ 220600 consisted of approximately 4400 shares of hologic common stock valued at $ 205500 , cash paid of $ 6900 , debt assumed of $ 5700 and approximately $ 2500 for acquisition related fees and expenses .the company determined the fair value of the shares issued in connection with the acquisition in accordance with eitf issue no .99-12 , determination of the measurement date for the market price of acquirer securities issued in a purchase business combination .the components and allocation of the purchase price , consists of the following approximate amounts: .
[['net tangible assets acquired as of july 13 2006', '$ 1200'], ['in-process research and development', '10200'], ['developed technology and know how', '39500'], ['customer relationship', '15700'], ['trade name', '3300'], ['order backlog', '800'], ['deferred income taxes', '4400'], ['goodwill', '145500'], ['estimated purchase price', '$ 220600']]
the company finalized and completed a plan to restructure certain of r2 2019s historical activities .as of the acquisition date the company recorded a liability of approximately $ 798 in accordance with eitf issue no .95-3 , recognition of liabilities in connection with a purchase business combination , related to the termination of certain employees and loss related to the abandonment of certain lease space under this plan .all amounts under this plan have been paid as of september 29 , 2007 .the company reduced goodwill related to the r2 acquisition in the amount of approximately $ 400 during the year ended september 29 , 2007 .the reduction was primarily related to a change in the preliminary valuation of certain assets and liabilities acquired based on information received during the year .the final purchase price allocations were completed within one year of the .

Question: what is the fair value of hologic common stock used for acquiring r2?
Answer: 46.7